Bangalore, India — 12/07/2017 — Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights
Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 2, 6, 3, 1, 11, 3 and 3 respectively.

Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
– The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 98 pages “Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Chemotherapy Induced Nausea and Vomiting – Overview, Chemotherapy Induced Nausea and Vomiting – Therapeutics Development, Chemotherapy Induced Nausea and Vomiting – Therapeutics Assessment, Chemotherapy Induced Nausea and Vomiting – Companies Involved in Therapeutics Development, Chemotherapy Induced Nausea and Vomiting – Drug Profiles, Chemotherapy Induced Nausea and Vomiting – Dormant Projects, Appendix. This report Covered Companies – Acacia Pharma Ltd, Aphios Corp, Astellas Pharma Inc, Athenex Inc, Camurus AB, Daewoong Pharmaceutical Co Ltd, Heron Therapeutics Inc, Insys Therapeutics Inc, Kyowa Hakko Kirin Co Ltd, MannKind Corp, Medlab Clinical Ltd, N4 Pharma Plc, Nanoform Cardiovascular Therapeutics Ltd, Nemus Bioscience Inc, RedHill Biopharma Ltd, Serina Therapeutics Inc, SoluBest Ltd, Suda Ltd, Tesaro Inc, Therapix Biosciences Ltd.

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/chemotherapy-induced-nausea-and-vomiting-pipeline-review-h2-2017

Find all Pharma and Healthcare Reports at – http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Pipeline Review, H2 2017 – Visit at – http://www.drugpipeline.net/global-markets-direct/integrin-beta-7-gut-homing-receptor-beta-subunit-or-itgb7-pipeline-review-h2

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Pipeline Review, H2 2017 – Visit at – http://www.drugpipeline.net/global-markets-direct/toll-receptor-4-htoll-or-cd284-or-tlr4-pipeline-review-h2-2017

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

Powered by WPeMatico